Table 1: Patients’ demographics by Gleason score at biopsy versus radical prostatectomy (RP).

FeatureGleason score value
Biopsy < RP (upgraded)Biopsy = RPBiopsy > RP (downgraded)

Overall128 (37.32%)186 (54.23%)29 (8.45%)
Age (Median/Min Max)62.76 (43–76)63.94 (46–76)63.55 (46–74)0.317
Race0.522
 White98 (76.56%)156 (83.87%)24 (82.76%)
 Black28 (21.88%)27 (14.52%)5 (17.24%)
 Yellow 2 (1.56%)3 (1.61%)0
PSA 10.29 (0.28–8.60)8.95 (0.6–29.7)11.1 (3.10–44)0.192
Prostate weight 37.45 (15–94)42.34 (11–190)42.30 (15–110)0.373
PSA density0.31 (0.06–0.86)0.25 (0.09–0.66)0.19 (0.03–0.63)<0.001
Clinical stage0.019
 T1c52 (44.44%)99 (56.25%)8 (30.77%)
 T2a46 (39.32%)58 (32.95%)10 (38.46%)
 T2b13 (11.11%)17 (9.66%)7 (26.02%)
 T2c6 (5.13%)2 (1.14%)1 (3.85%)
Biopsy Gleason score<0.001
 ≤6115 (89.84%)99 (53.23%)0
 713 (10.16%)84 (45.16%)19 (65.52%)
 ≥80 3 (1.61%)10 (34.48%)
Pathological Gleason score<0.001
 ≤60100 (53.76%)18 (62.07%)
 7112 (87.50%)83 (44.62%)11 (37.93%)
 ≥816 (12.50%)3 (1.61%)0
Pathological stage0.05
 ≤pT281 (63.28%)139 (74.73%)23 (79.31%)
47 (36.72%)47 (25.27%)6 (20.69%)
Positive points (tumor extent)
 ≤2644 (37.93%)98 (55.06%)15 (60.00%)0.009
72 (62.07%)80 (44.94%)10 (40.00%)
Positive points (median/min max)46.70 (1.00–33.50)29.76 (0–222)33.32 (1.0–152)<0.001
“Insignificant” tumors*<0.001
 Yes0 (0.00%)22 (12.43%)3 (12.50%)
 No 116 (100.00%)155 (87.57%)21 (87.50%)
Positive surgical margin<0.001
 No51 (40.16%)114 (61.29%)20 (68.97%)
 Yes76 (59.84%)72 (38.71%)9 (31.03%)
Extra prostatic extension0.043
 No81 (63.78%)141 (75.81%)23 (79.31%)
 Yes46 (36.22%)45 (24.19%)6 (20.69%)
Seminal vesicle invasion0.003
 No 103 (82.40%)174 (94.57%)25 (86.21%)
 Yes22 (17.60%)10 (5.43%)4 (13.79%)

 *Based on classification of Billis et al. [6].